피하 약물전달 기기 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Subcutaneous Drug Delivery Devices Market size is expected to reach USD 83.73 Billion in 2034 from USD 41.64 Billion (2025) growing at a CAGR of 8.07% during 2026-2034.

The global subcutaneous drug delivery devices market has grown significantly as healthcare providers increasingly adopt convenient and patient-friendly treatment methods. These devices deliver medications beneath the skin, allowing drugs to be absorbed slowly into the bloodstream. They are widely used for managing chronic conditions such as diabetes, autoimmune diseases, and hormonal disorders. The increasing preference for self-administration therapies has supported the expansion of this market.

Market growth is driven by the rising prevalence of chronic diseases that require long-term medication. Patients and healthcare providers favor subcutaneous delivery devices because they reduce the need for frequent hospital visits and simplify treatment routines. Advances in medical device technology have also improved device accuracy, safety, and ease of use, making them suitable for home-based care.

The future outlook for the subcutaneous drug delivery devices market remains promising as pharmaceutical companies continue to develop biologic drugs that require specialized delivery systems. Innovations in wearable injectors and smart drug delivery devices may further improve patient adherence to treatment. Expanding healthcare access and increasing adoption of home healthcare solutions are expected to drive continued market growth.

MARKET SEGMENTATION

By Product Type

• Prefilled Syringes
• Autoinjectors
• Wearable Injectors
• Others

By Application

• Diabetes
• Oncology
• Autoimmune Diseases
• Others

By End-User

• Hospitals
• Clinics
• Home Care Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Johnson Johnson, Sanofi SA, Pfizer Inc, Abbott Laboratories, GlaxoSmithKline plc, Bayer AG, Novartis AG, Merck Co Inc, F HoffmannLa Roche Ltd, Novo Nordisk AS, Medtronic plc, Becton, Dickinson and Company BD, Insulet Corporation, AstraZeneca plc, Amgen Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Prefilled Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Autoinjectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Wearable Injectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Home Care Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product Type
  • 8.2.2 By Application
  • 8.2.3 By End-user
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product Type
  • 8.3.2 By Application
  • 8.3.3 By End-user
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product Type
  • 8.4.2 By Application
  • 8.4.3 By End-user
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product Type
  • 8.5.2 By Application
  • 8.5.3 By End-user
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product Type
  • 8.6.2 By Application
  • 8.6.3 By End-user
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Johnson & Johnson
  • 10.2.2 Sanofi S.A
  • 10.2.3 Pfizer Inc
  • 10.2.4 Abbott Laboratories
  • 10.2.5 GlaxoSmithKline Plc
  • 10.2.6 Bayer AG
  • 10.2.7 Novartis AG
  • 10.2.8 Merck & Co. Inc
  • 10.2.9 F. Hoffmann-La Roche Ltd
  • 10.2.10 Novo Nordisk A/S
  • 10.2.11 Medtronic Plc
  • 10.2.12 Becton
  • 10.2.13 Dickinson And Company (BD)
  • 10.2.14 Insulet Corporation
  • 10.2.15 AstraZeneca Plc
  • 10.2.16 Amgen Inc